Literature DB >> 20404250

Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

Malcolm A Smith1, Nita L Seibel, Sean F Altekruse, Lynn A G Ries, Danielle L Melbert, Maura O'Leary, Franklin O Smith, Gregory H Reaman.   

Abstract

PURPOSE: This report provides an overview of current childhood cancer statistics to facilitate analysis of the impact of past research discoveries on outcome and provide essential information for prioritizing future research directions.
METHODS: Incidence and survival data for childhood cancers came from the Surveillance, Epidemiology, and End Results 9 (SEER 9) registries, and mortality data were based on deaths in the United States that were reported by states to the Centers for Disease Control and Prevention by underlying cause.
RESULTS: Childhood cancer incidence rates increased significantly from 1975 through 2006, with increasing rates for acute lymphoblastic leukemia being most notable. Childhood cancer mortality rates declined by more than 50% between 1975 and 2006. For leukemias and lymphomas, significantly decreasing mortality rates were observed throughout the 32-year period, though the rate of decline slowed somewhat after 1998. For remaining childhood cancers, significantly decreasing mortality rates were observed from 1975 to 1996, with stable rates from 1996 through 2006. Increased survival rates were observed for all categories of childhood cancers studied, with the extent and temporal pace of the increases varying by diagnosis.
CONCLUSION: When 1975 age-specific death rates for children are used as a baseline, approximately 38,000 childhood malignant cancer deaths were averted in the United States from 1975 through 2006 as a result of more effective treatments identified and applied during this period. Continued success in reducing childhood cancer mortality will require new treatment paradigms building on an increased understanding of the molecular processes that promote growth and survival of specific childhood cancers.

Entities:  

Mesh:

Year:  2010        PMID: 20404250      PMCID: PMC2881732          DOI: 10.1200/JCO.2009.27.0421

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  57 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation.

Authors:  P R Thomas; M Deutsch; J L Kepner; J M Boyett; J Krischer; P Aronin; L Albright; J C Allen; R J Packer; R Linggood; R Mulhern; J A Stehbens; J Langston; P Stanley; P Duffner; L Rorke; J Cherlow; H S Friedman; J L Finlay; T J Vietti; L E Kun
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

3.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

Authors:  Holcombe E Grier; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; James S Miser
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

4.  Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.

Authors:  Bruce C Bostrom; Martha R Sensel; Harland N Sather; Paul S Gaynon; Mei K La; Katherine Johnston; Gary R Erdmann; Stuart Gold; Nyla A Heerema; Raymond J Hutchinson; Arthur J Provisor; Michael E Trigg
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

5.  Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.

Authors:  James S Miser; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; Holcolmbe E Grier
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

6.  Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies.

Authors:  Norman E Breslow; San-San Ou; J Bruce Beckwith; Gerald M Haase; John A Kalapurakal; Michael L Ritchey; Robert C Shamberger; Patrick R M Thomas; Giulio J D'Angio; Daniel M Green
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

7.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

Authors:  Deborah A Thomas; Stefan Faderl; Jorge Cortes; Susan O'Brien; Francis J Giles; Steven M Kornblau; Guillermo Garcia-Manero; Michael J Keating; Michael Andreeff; Sima Jeha; Miloslav Beran; Srdan Verstovsek; Sherry Pierce; Laurie Letvak; August Salvado; Richard Champlin; Moshe Talpaz; Hagop Kantarjian
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

8.  Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.

Authors:  Leo Kager; Andreas Zoubek; Ulrike Pötschger; Ulrike Kastner; Silke Flege; Beate Kempf-Bielack; Detlev Branscheid; Rainer Kotz; Mechthild Salzer-Kuntschik; Winfried Winkelmann; Gernot Jundt; Hartmut Kabisch; Peter Reichardt; Heribert Jürgens; Helmut Gadner; Stefan S Bielack
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

9.  All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

Authors:  Martin S Tallman; Janet W Andersen; Charles A Schiffer; Frederick R Appelbaum; James H Feusner; William G Woods; Angela Ogden; Howard Weinstein; Lois Shepherd; Cheryl Willman; Clara D Bloomfield; Jacob M Rowe; Peter H Wiernik
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

10.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.

Authors:  Kirk R Schultz; W Paul Bowman; Alexander Aledo; William B Slayton; Harland Sather; Meenakshi Devidas; Chenguang Wang; Stella M Davies; Paul S Gaynon; Michael Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew Carroll; Nyla A Heerema; Naomi Winick; Michael J Borowitz; Stephen P Hunger; William L Carroll; Bruce Camitta
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

View more
  342 in total

1.  Computerized provider order entry in pediatric oncology: design, implementation, and outcomes.

Authors:  Allen R Chen; Christoph U Lehmann
Journal:  J Oncol Pract       Date:  2011-07       Impact factor: 3.840

2.  Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Authors:  E L Carpenter; E A Haglund; E M Mace; D Deng; D Martinez; A C Wood; A K Chow; D A Weiser; L T Belcastro; C Winter; S C Bresler; M Vigny; P Mazot; S Asgharzadeh; R C Seeger; H Zhao; R Guo; J G Christensen; J S Orange; B R Pawel; M A Lemmon; Y P Mossé
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

3.  Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children's oncology group.

Authors:  Alena Y Z Edwards; Jeffrey M Skolnik; Erin Dombrowsky; Dimple Patel; Jeffrey S Barrett
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

4.  Is routine pelvic surveillance imaging necessary in patients with Wilms tumor?

Authors:  Sue C Kaste; Samuel L Brady; Brian Yee; Valerie J McPherson; Robert A Kaufman; Catherine A Billups; Najat C Daw; Alberto S Pappo
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

5.  Stereotactic radiation therapy for progressive residual pilocytic astrocytomas.

Authors:  Karlo J Lizarraga; Alessandra Gorgulho; Steve P Lee; Glenn Rauscher; Michael T Selch; Antonio A F DeSalles
Journal:  J Neurooncol       Date:  2012-05-27       Impact factor: 4.130

6.  Pediatric high-grade gliomas: survival at what cost?

Authors:  Katherine E Warren
Journal:  Transl Pediatr       Date:  2012-10

Review 7.  Treatment of pediatric cerebral radiation necrosis: a systematic review.

Authors:  N Drezner; K K Hardy; E Wells; G Vezina; C Y Ho; R J Packer; E I Hwang
Journal:  J Neurooncol       Date:  2016-07-20       Impact factor: 4.130

8.  Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.

Authors:  P M Anderson; P Meyers; E Kleinerman; K Venkatakrishnan; D P Hughes; C Herzog; W Huh; R Sutphin; Y M Vyas; V Shen; A Warwick; N Yeager; C Oliva; B Wang; Y Liu; A Chou
Journal:  Pediatr Blood Cancer       Date:  2013-08-31       Impact factor: 3.167

9.  The Children's Oncology Group's 2013 five year blueprint for research.

Authors:  Peter C Adamson
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 10.  Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.

Authors:  Stephen P Hunger; Mignon L Loh; James A Whitlock; Naomi J Winick; William L Carroll; Meenakshi Devidas; Elizabeth A Raetz
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.